Using Cox survival analysis, we found that patients with higher co‐expressions of Gal‐3 and CXCR2 had a significantly worse survival rate (Figure 7E) and that Gal‐3 expression correlated with CXCR2 expression, tumour progression and prognosis in RCC. This evidence concerns the gene CXCR2 and neoplasm.